Stratagene Launches ArrayAssist(R) CopyNumber; Only Guided Workflow Available to Biologists for Copy Number Analysis
Stratagene Corporation (NASDAQ:STGN), a leading developer, manufacturer and marketer of specialized life science research and diagnostic products, today announced the launch of its ArrayAssist(R) Copy Number Software. This powerful yet extremely intuitive software is the only guided workflow presently available for copy number analysis, enabling researchers to easily manipulate and analyze the massive data sets generated by leading chromosomal copy number microarrays.
The ArrayAssist Copy Number software is Stratagene's most recent application on the ArrayAssist platform, which includes ArrayAssist(R) Expression and ArrayAssist(R) Exon, the latest versions of which were introduced in January 2006. All ArrayAssist applications have earned GeneChip-compatible status with the Affymetrix platform. They will soon be provided as universal binaries, able to run natively on the latest Intel-based Macintosh(R) computers, and are compatible with Mac(R) OS X, Windows(R), and Linux(R).
"Our ArrayAssist platform is deliberately designed to make sophisticated, high-density array analysis accessible to the life scientist," said David Edwards, Director, Software Solutions at Stratagene. "The most current microarrays for exon, copy number and expression analysis generate data sets that break most traditional analytical tools. With a full spectrum of advanced analytical features and dynamic interactive visualizations, Stratagene's intuitive, easy-to-use ArrayAssist platform helps biologists and biostatisticians conduct independent advanced microarray data analysis."
ArrayAssist Copy Number supports the identification of biomarkers for cancer, degenerative disease and developmental disorders by highlighting chromosomal amplifications and deletions. Biologists can compare their experimental data in ArrayAssist CopyNumber with a reference genome using ArrayAssist's integrated genome browser, a feature of all ArrayAssist applications, and map biological pathways for a comprehensive understanding of the relevant relationships in their system with the integration of Stratagene's PathwayArchitect platform.
Stratagene will be demonstrating ArrayAssist Copy Number in Booth #6 at the Cambridge HealthTech Institute's Microarray Data Analysis and Interpretation conference, being held at the Ritz-Carlton in Washington D.C., from August 23 to 25, 2006.
Stratagene's ArrayAssist and PathwayArchitect products suites are powered by the award-winning avadis technology and are co-developed with Strand Life Sciences.
About ArrayAssist
The ArrayAssist product suite provides easy to use, biology-focused workflows designed to process a wide variety of gene expression arrays, from raw .CEL data through primary expression and quality analysis to advanced gene-level and exon-level analysis. It has a comprehensive suite of tools to examine both transcriptional and splicing regulation using the Affymetrix GeneChip arrays as well as advanced analytical features such as multi-way ANOVA, non-parametric statistical tests, classifiers for machine learning-based prediction and sophisticated, interactive visualization options. The ArrayAssist Expression, ArrayAssist Exon, and ArrayAssist Copy Number products are fully integrated with Stratagene's PathwayArchitect systems biology pathway analysis software.
About Stratagene Corporation
Stratagene is a developer, manufacturer and marketer of specialized life science research and diagnostic products. The Company's life science research unit supports advances in science by inventing, manufacturing and distributing products that simplify, accelerate and improve research. These products are used throughout the academic, industrial and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. The Company's diagnostic unit develops and manufactures products for urinalysis, and high quality automated instrument and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, as well as its experience with FDA regulatory procedures, the Company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation. More information is available at http://www.stratagene.com.